aTyr Pharma, Inc.
ATYR
$0.85
$0.0810.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 43.85% | 30.22% | |||
| Gross Profit | -42.62% | -30.22% | |||
| SG&A Expenses | -2.52% | 24.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.60% | 28.78% | |||
| Operating Income | -31.66% | -28.78% | |||
| Income Before Tax | -31.81% | -31.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.81% | -31.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 100.00% | 0.00% | |||
| Net Income | -31.81% | -31.26% | |||
| EBIT | -31.66% | -28.78% | |||
| EBITDA | -31.93% | -29.10% | |||
| EPS Basic | -22.29% | -25.92% | |||
| Normalized Basic EPS | -22.30% | -25.95% | |||
| EPS Diluted | -22.29% | -25.92% | |||
| Normalized Diluted EPS | -22.30% | -25.95% | |||
| Average Basic Shares Outstanding | 7.80% | 4.20% | |||
| Average Diluted Shares Outstanding | 7.80% | 4.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||